Terumo has agreed to acquire OrganOx for about US$1.5bn, entering organ transplantation technology to expand access to preservation devices.
Announced on 25 August 2025, the definitive agreement dated 23 August will make OrganOx a wholly owned subsidiary of Terumo and signals its entry into transplant-related care.
OrganOx specialises in normothermic machine perfusion (NMP), devices that circulate warm, oxygen- and nutrient-rich fluid through an organ outside the body to keep it viable and allow real-time monitoring. The aim is to increase organ utilisation, enable use of marginal donor organs, and improve post-transplant outcomes while reducing night-time or emergency procedures.
The company’s liver NMP device, metra, gained FDA approval in 2021 and launched in the US in 2022. It also holds approvals in the EU, UK, Australia and Canada, and has been used in more than 6,000 liver transplants worldwide. A kidney NMP device is in development, with commercialisation targeted around 2030.
Terumo said the deal broadens access to preservation technology amid organ shortages — in the US alone, about 6,000 people on waiting lists die each year without a transplant. Terumo Ventures made a strategic investment in OrganOx in March 2025.
“We are thrilled to welcome OrganOx — a leading innovator in organ preservation technology — into the Terumo Group, marking our entry into the organ transplantation field,” said Hikaru Samejima, chief executive of Terumo. “Donated organs are an extremely precious medical resource, and OrganOx’s mission to deliver transplantable organs in optimal condition deeply resonates with our unwavering commitment to patients.”
“OrganOx is a pioneer and leader in organ transplantation technology,” said Oern R. Stuge, executive chairman of OrganOx. “Today’s announced transaction is expected to expand the adoption of our transplantation technology platform by leveraging Terumo’s global infrastructure to benefit more patients around the globe.”
